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HAI Peptide and Backbone 
Analogs—Validation and 
Enhancement of Biostability and 
Bioactivity of BBB Shuttles
Pol Arranz-Gibert1, Roger Prades1, Bernat Guixer1, Simón Guerrero2,3, Eyleen Araya3,4, 
Sonia Ciudad1, Marcelo J. Kogan2,3, Ernest Giralt1,5 & Meritxell Teixidó1
Low effectiveness and resistance to treatments are commonplace in disorders of the central 
nervous system (CNS). These issues concern mainly the blood-brain barrier (BBB), which preserves 
homeostasis in the brain and protects this organ from toxic molecules and biohazards by regulating 
transport through it. BBB shuttles—short peptides able to cross the BBB—are being developed to help 
therapeutics to cross this barrier. BBB shuttles can be discovered by massive exploration of chemical 
diversity (e.g. computational means, phage display) or rational design (e.g. derivatives from a known 
peptide/protein able to cross). Here we present the selection of a peptide shuttle (HAI) from several 
candidates and the subsequent in-depth in vitro and in vivo study of this molecule. In order to explore 
the chemical diversity of HAI and enhance its biostability, and thereby its bioactivity, we explored two 
new protease-resistant versions of HAI (i.e. the retro-D-version, and a version that was N-methylated 
at the most sensitive sites to enzymatic cleavage). Our results show that, while both versions of HAI are 
resistant to proteases, the retro-D-approach preserved better transport properties.
From a therapeutic perspective, peptides are chemical structures that fall half-way between small molecules and 
biologics (e.g. antibodies). The latter show a better profile to interact with high affinity with the target mole-
cule; however, their complexity does not allow their chemical synthesis and makes it difficult to obtain them as 
well-defined products1. Furthermore, such macromolecules can give rise to immunogenicity concerns and they 
are not suitable for oral delivery therapies. In contrast, small molecules have opposite properties. Peptides can be 
synthesized chemically through a well-established methodology, i.e. solid-phase peptide synthesis (SPPS)2, and 
can be well-characterized through analytical methods. In addition, their short length reduces the risk of trigger-
ing an immunological response, while having a sufficient active surface for high affinity and specific interaction 
with the target molecule3.
In this regard, research efforts are being channeled into peptides that have the capacity to cross the blood-brain 
barrier (BBB), namely BBB shuttles4,5, and that can thus facilitate the transport of molecules that are otherwise 
unable to reach the brain parenchyma alone. The BBB is an active and selective barrier that protects the cen-
tral nervous system (CNS)6–8. Thus, BBB shuttles allow the delivery of therapeutics into the CNS through a 
non-invasive approach. Two clearly differentiated routes, namely passive diffusion (i.e. lipophilic pathway)9 and 
active transport (mainly, adsorptive- or receptor-mediated transcytosis, AMT and RMT, respectively), are the 
most suitable approaches for drug delivery to the brain10. The former is conveniently used for small cargos, while 
the latter enables the delivery of large therapeutics, such as proteins and nanoparticles (NPs)10,11.
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Discovery of peptide BBB shuttles can be pursued by extensive exploration of chemical diversity, rational 
design from proteins that interact with cellular receptors that are internalized by endocytosis (and can be translo-
cated by transcytosis). Here, we report (1) the study of six peptides (TAT, Antennapedia, R8, SAP, RVG and HAI) 
known to be internalized by adsorptive- or receptor-mediated endocytosis (AME and RME, respectively), (2) the 
subsequent deeper study in vitro and in vivo of the best hit (HAI) and (3) the improvement of its bioactivity by 
means of backbone redesign to enhance resistance to proteases.
Results and Discussion
Selection of Initial Candidates. Discovered in 1988, HIV TAT 48–57 peptide derives from the transcrip-
tional trans-activator protein of the human immunodeficiency virus 1 (HIV-1)12,13. TAT is one of the most widely 
used molecular beacons for cellular drug delivery14, and it has already been used as a BBB shuttle15–19, includ-
ing the transport of quantum dots (QDs)20, which enabled to study the mechanism underlying the capacity of 
this peptide to transport NPs. Antennapedia, also known as penetratin21, was discovered in 1994 and, together 
with TAT, it was one of the first cell-penetrating peptides (CPPs) to be reported. Derived from the third helix 
of the Antennapedia homeodomain of Drosophila, it has been used as a vector for the delivery of range of car-
gos into cells22, for intestinal absorption23, and for brain delivery24. Inspired by the common features of TAT 
and Antennapedia, Futaki et al. designed and synthesized a library of oligoarginine peptides (Rn)25.These pep-
tides translocate across cell membranes in a similar manner to that used by TAT and Antennapedia, especially 
the R8 and R12 peptides, which show high penetration efficiency. Although there are some concerns about their 
cytotoxicity26, oligoarginine peptides are among the most efficient CPPs with respect to translocation across cell 
membranes. Their use as BBB shuttles has not been reported to date. Sweet Arrow Peptide (SAP) has a Pro-rich 
structure and is derived from the N-terminal domain of γ-zein, a maize storage protein27. One of its main features 
is its efficiency to translocate across cell membranes without presenting toxicity, both in vitro27 and in vivo28. 
SAP was discovered by our group, and to date there are no published data about its capacity as a BBB shuttle. 
A 29-amino acid peptide derived from rabies virus glycoprotein, so-called RVG, targets the nicotinic acetyl-
choline receptor (nAChR)29, widely expressed in the brain, including the endothelial cells of brain capillaries30. 
This peptide has been successfully used as a BBB shuttle for the delivery of small interfering RNA (siRNA) in 
mice31. Finally, the peptide HAI was found by Lee et al. by phage display against the human transferrin receptor 
(TfR)32. Highly expressed in brain capillaries, TfR mediates the delivery of iron to the brain33. It is also expressed 
in choroid plexus epithelial cells and neurons34. One of the main advantages of this peptide is that it interacts in a 
region of the TfR that does not overlap with the native binding site of transferrin, thereby avoiding physiological 
effects on the protein function in vivo and consequently making this peptide very attractive from the therapeutic 
point of view. HAI has been studied for diverse applications such as tumor-targeting35 and oral drug delivery36. 
Its potential as a BBB shuttle has recently been addressed by Kuang et al.37. Given that other peptides interacting 
with the TfR have the capacity to cross the BBB10 and that the BBB endothelium is characterized by high presence 
of TfR38—a feature that can selectively enhance brain targeting—here we expand on the potential applications of 
HAI as a BBB shuttle.
Internalization and Transport of Peptide Candidates —in vitro Studies. Screening of compounds 
as potential candidates for specific therapeutic applications usually involves in vitro experiments. Their imple-
mentation helps to both simplify the system of study and reduce the experimental cost and the number of exper-
imentation animals used. In recent decades, such models have been extended to the study of the BBB39,40, thus 
enabling the quantification of transport for individual compounds. Here we initially screened the selected BBB 
shuttle candidates in a series of in vitro BBB models in order to select the peptide with the best performance for 
further study and development.
Initially, peptides labeled at the N-terminus with carboxyfluorescein (Cf) were incubated with bovine brain 
endothelial cells (BBECs) or rat astrocytes at 50 μM (except R8, assayed at 15 μM to avoid cytotoxicity) in order 
to determine their internalization capacity, a necessary but not sufficient condition to cross the BBB. Cells were 
then analyzed by confocal laser scanning microscopy (CLSM) and by flow cytometry (Fig. 1). The data from these 
experiments revealed that the three CPPs (TAT, penetratin and R8) showed the highest internalization profiles in 
both cell types. Nevertheless, greater internalization does not necessarily equate to better transcytosis, since high 
retention in cells would prevent the peptide from crossing from the apical to the basal side (brain parenchyma).
In a subsequent step we evaluated the transport capacity of these peptides using two in vitro barrier models, 
namely in an intestine (Caco-2 assay)41 and a BBB model39,40 (Table 1). In these models, two compartments are 
separated by a membrane containing a monolayer of endothelial cells which mimics either the intestinal barrier 
or the BBB. One compartment contains the peptide, which is incubated for 2 h. The amount of peptide in each 
compartment is then analyzed to determine apparent permeability (Papp, in cm/s) and transport (T, in %). The 
integrity of the compound in the acceptor compartment is assessed by mass spectrometry (MS). Our results show 
that only penetratin and HAI crossed the intestinal barrier (and only penetratin, R8 and HAI were detected by 
MALDI-TOF MS in acceptor wells) while HAI showed the best performance in the BBB model (only TAT was 
not detected by MALDI-TOF MS in acceptor wells). Thus, we turned our attention to HAI to further study its 
potential as BBB shuttle.
Studying the Selected Candidate—Mechanistic in vitro Studies, in vivo Transport Efficiency 
and Biostability. We devised a series of experiments to ensure that HAI delivery is TfR-dependent, and at 
the same time to establish whether it competes with Tf—an observation previously reported32,42. HAI transport 
(cellular internalization) was promoted by the addition of Tf, the natural ligand of TfR, which might induce the 
internalization and transcytosis of the aforementioned receptor by the cells (Fig. 2a,b). Thus, the peptide did not 
compete with Tf for the same binding pocket at TfR. Moreover, competition assays revealed that HAI competes 
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Figure 1. Peptide internalization by cells. CLSM images of (a) BBECs and (b) rat astrocytes incubated with 
the candidates at a concentration of 50 μM (R8 was incubated at a concentration of 15 μM) at 37 °C for 3 h. 
Flow cytometry results after incubating (c) BBECs and (d) rat astrocytes with each peptide under the same 
experimental conditions as previously described. Data are expressed as the mean ± SD.
Peptide
Caco-2 BBB
Papp (×10−10 cm/s) T (%) Papp (×10−6 cm/s) T (%)
TAT 0 0 0 0
Penetratin 4.2 ± 1.3 1.6 ± 0.5 3.0 ± 0.6 1.8 ± 0.2
R8 0 0 0.60 ± 0.06 0.68 ± 0.07
SAP 0 0 5.5 ± 1.5 5 ± 3
RVG 0 0 0.28 ± 0.02 0.29 ± 0.03
HAI 2.0 ± 0.8 0.7 ± 0.3 18 ± 2 16 ± 3
Table 1. Caco-2 and in vitro bovine BBB model permeability results (mean ± SD). Candidates were incubated 
for 2 h at 37 °C using HBSS as buffer and then analyzed by RP-HPLC to determine transport and Papp.
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with itself for internalization (Fig. 2c), and incubation of cells with increasing concentrations of the peptide led 
to the saturation of internalization (Fig. 2d). Both observations indicate that HAI is actively transported. Finally, 
we show that this peptide co-localizes with Tf when cells are incubated with carboxyfluorescein (Cf)-labeled HAI 
(Cf-HAI) and Alexa555-Tf (Fig. 2e). This observation thus demonstrates that the internalization of HAI occurs 
through clathrin-mediated endocytosis, as already described for the TfR-Tf pair.
Furthermore, HAI was characterized by circular dichroism (CD). This approach revealed a profile like that 
of a random coil conformation (Figure S2), with a negative band at 197 nm and a weak band at 220 nm. Toxicity 
assays demonstrated that the peptide is not toxic for BBECs or rat astrocytes, when these cells are incubated with 
the peptide at a concentration of 50 μM for 24 h (see Figure S3a,b).
To study the in vitro and in vivo potential of HAI to deliver a larger cargo to the CNS, we decorated gold 
nanoparticles (AuNPs) with this peptide (see full characterization in Figures S4–S6, Table S2). We first discarded 
cytotoxicity arisen (Figure S7) by these constructs to subsequently evaluate their transport in the previously used 
bovine BBB in vitro model (Fig. 3a)39,40. We ensured that the size of our AuNPs and conjugates were adequate 
(i.e. small enough) for in vivo purposes but at the same time larger than 20 nm and thus avoiding alteration of 
the peptide structure (Figure S6)43. Incubation of the cells with AuNP-HAI at a concentration of 5 nM caused an 
increase in transport by more than two orders of magnitude, up to 1.7 (0.1) × 10−7 cm/s, compared to AuNPs 
(0.97 (0.003) × 10−9 cm/s). In addition, we compared these results with those of a previously studied BBB shuttle 
(THR) carrying the same NPs Prades et al. HAI conjugates showed slightly higher permeability than AuNP-THR, 
1.40 (0.07) × 10−7 cm/s11.
To compare the delivery of AuNP, AuNP-HAI and AuNP-THR to the brain, in vivo experiments in rats were 
performed (the latter results, compared from Prades et al.)11. Animals were euthanized at different times (0.5, 1 and 
2 h) after i.p. injection. Brains were excised after PBS perfusion. They were lyophilized and dried to proceed with 
their gold-content quantification by instrumental neutron activation analysis (INAA)—samples are irradiated with 
neutrons, converting 197Au to 198Au and leading to γ ray emission that can be quantified. Trace levels of gold found 
Figure 2. Studies of the internalization mechanism of HAI: flow cytometry results after incubating (a) bovine 
brain endothelial cells (BBECs) or (b) rat astrocytes with Cf-HAI at 50 μM in the absence or presence of 
transferrin, (c) co-incubation of Cf-HAI with HAI (competition assay), (d) incubation of BBECs with a range 
of concentrations of Cf-HAI, and (e) co-incubation of (left) BBECs or (right) rat astrocytes (co-localization 
experiments) with Cf-HAI at 50 μM with fluorescently labeled transferrin (AlexaFluor555). Data are expressed 
as mean ± SD.
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in the CNS are around 2 × 105 mg/kg fresh tissue44. Our samples showed a significantly much higher gold content. 
Furthermore, the conjugation of AuNPs to HAI and THR increased the concentration of this metal in the brain 
with respect to naked AuNPs (Fig. 3b). Remarkably, AuNP-HAI showed greater penetration than AuNP-THR.
HAI showed excellent transport through the BBB, thus emerging as a promising BBB shuttle. Nevertheless, 
peptides formed by L-amino acids have a short in vivo half-life in serum, which can reduce their potential bioac-
tivity. The sensitivity of this peptide to proteases was tested at a concentration of 150 μM in HBSS/human serum 
90:10 (v/v) for 24 h. At several time points, an aliquot was extracted, precipitated serum proteins with MeOH and 
then analyzed by RP-HPLC. The peptide showed a half-life in serum of around 5 min, a much shorter time than 
that expected for a drug-like compound. The potential proteolytic sites were analyzed by MALDI-TOF, which 
revealed three main proteolytic sensitive sites: H-HA↓I↓YPR↓H-NH2 (where ↓ shows the cleavage between two 
consecutive residues; see Figs 4a,b and S9,S10).
Tuning Protease-Resistance: N-Methylation of Labile Positions vs. the Retro-D-Version Approach. 
Several strategies can be used to increase the in vivo stability of a peptide composed of L-amino acids. Here we selected 
the N-methylation of sites sensitive to proteolysis and the retro-enantio approach, which is a topological mimic 
with a reversed sequence order and inversed stereochemistry in each α-carbon (i.e. made by D-amino acids)45. 
The N-methylated peptide designed was H-HA(NMe)I(NMe)YPR(NMe)H-NH2, which contained the sensitive 
sites (see previous section) protected with an N-methyl group46,47, namely (NMe)HAI. The retro-enantio peptide 
(or retro-D) was H-hrpyiah-NH2 (where the lowercase letter denotes D-amino acid), namely rD-HAI. Thus, we 
synthesized and studied the stability of these two peptides in serum (Figs 4c–f and S9). Both displayed excellent 
protease resistance (half-life above 24 h).
Characterization of peptides by CD revealed random coil conformation like that of the parent version (Figure S2), 
meaning that in solution they do not adopt a preferential conformation. Similarly, like the parent peptide, the two 
protease-resistant analogs did not show toxicity up to 50 μM, as indicated by the MTT assay at 24 h (Figure S3c,d).
We then studied the capacity of these peptides to be internalized by and transported through the endothelium 
of the BBB or intestine. Thus, we evaluated their transport capacity using the two previously used in vitro barrier 
models, i.e. Caco-2 and BBB assays. All the peptides were detected by MALDI-TOF MS in the acceptor wells. 
The (NMe)HAI analog displayed a two-fold increase in internalization with respect to the parent version (Fig. 5), 
while rD-HAI maintained the internalization rate in BBECs and rat astrocytes.
The in vitro barrier model of the BBB revealed discrepancies in transport rate (Table 2). rD-HAI displayed the 
highest value (around 1.5 times the rate of the parent version), while (NMe)HAI recorded an intermediate value. 
The discrepancy between internalization and transport of (NMe)HAI is probably due to an increase in lipophilic-
ity after methylation of the backbone, thereby enhancing internalization by passive diffusion but not favoring the 
transcytosis. To ensure that rD-HAI crosses the BBB through active transport, we proceeded to test its mecha-
nism of transport using a human model of the BBB. The peptide was assayed at increasing concentrations in an in 
vitro human BBB model (Figure S12), observing saturation of transport—typical of active transport.
Conclusion
We first selected the peptide HAI among a set of peptides known to be endocytosed by AME or RME, and then 
further explored its capacity as a shuttle. The peptide was able to deliver AuNPs to the brains of rats and showed 
better transport capacity than a previous peptide studied by our laboratory (namely THR). In addition, two 
strategies through which to increase the protease-resistance of a peptide, namely the use of the retro-D-version 
Figure 3. In vitro and in vivo transport of AuNPs (mean ± SD). Using the same in vitro bovine BBB transport 
model used for the peptides analyzed previously; (a) apparent permeability (Papp) was obtained for AuNPs and 
AuNP-HAI. Then, (b) in vivo studies were performed in rats to confirm the capacity of HAI to deliver AuNPs 
into the CNS. In these experiments, the corresponding AuNPs were injected i.p. using 1.86 mg gold content per 
kg of body weight. The gold content in the brain was determined by INAA at three timepoints (0.5, 1, 2 h). In (a) 
data was analyzed using the t-test, ****P < 0.0001. In (b), the one-way ANOVA analysis was applied, *P < 0.5, 
**P < 0.01, ***P < 0.001, ****P < 0.0001. Data for AuNP-THR obtained from Prades et al.11.
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or the N-methylation of the most sensitive sites, were applied to HAI. While (NMe)HAI showed an enhance-
ment in internalization, its permeability through in vitro transport models did not increase—the hydrophobicity 
increase by N-methylation of the backbone may have enhanced internalization by other mechanism, i.e. passive 
diffusion. In contrast, the retro-D-approach appeared to preserve the shuttle properties (similar internalization), 
while enhancing its biostability and permeability; obtaining a lead BBB shuttle from a validated hit (HAI) using 
in vitro and in vivo experiments.
Methods
Materials and Methods. Protected amino acids and resins were supplied by Luxembourg Industries 
(Tel-Aviv, Israel), Neosystem (Strasbourg, France), Calbiochem-Novabiochem AG (Laüfelfingen, Switzerland), 
PolyPeptide Laboratories (Torrance, CA, USA), Bachem AG (Bubendorf, Switzerland), and Iris Biotech 
(Marktredwitz, Germany). DIEA and ninhydrin were from Fluka Chemika (Buchs, Switzerland). Solvents for 
peptide synthesis and RP-HPLC were supplied by Scharlau or SDS (Barcelona, Spain). Trifluoroacetic acid was 
purchased from KaliChemie (Bad Wimpfen, Germany). The other chemicals used were from Aldrich (St. Louis, 
MO, USA) and were of the highest purity commercially available. Mass spectra were recorded on an Applied 
Biosystems 4700 MALDI-TOF spectrometer (PE Applied Biosystems, Foster City, CA, USA), using an ACH 
matrix. High-resolution mass spectra were recorded on a Synapt HDMS (Waters, Manchester, UK) and on a 
LTQ-FT Ultra (Thermo Scientific, Waltham, MA, USA). RP-HPLC chromatograms were recorded on a Waters 
model Alliance 2695 with photodiode array (PDA) detector 996 from Waters (Waters, Milford, CT, USA) 
using a SunFire C18 column (150 × 4.6 mm × 5 µm, 100 Å, Waters); solvents: H2O (0.045% TFA) and CH3CN 
(0.036% TFA); flow rate of 1 mL/min; and software Millenium version 4.0. HPLC-MS [Waters model Alliance 
Figure 4. Stability of HAI, rD-HAI and (NMe)HAI in human serum: (a,c,e) graphic representation of the 
remaining peptide vs. time for each peptide (mean ± SD), respectively; (b) MALDI-TOF traces of HAI peptide 
after 30 min; (d,f) structures of the peptides rD-HAI and (NMe)HAI, respectively.
www.nature.com/scientificreports/
7ScIenTIfIc REPORTS |         (2018) 8:17932  | DOI:10.1038/s41598-018-35938-8
2796, quaternary pump, Waters 2487 with UV/Vis dual absorbance detector, ESI-MS model Micromass ZQ and 
Masslynx version 4.0 software (Waters)] was done using a SunFire C18 column (150 × 3.9 mm × 5 µm, 300 Å, 
Waters); solvents: H2O (0.1% formic acid) and CH3CN (0.07% formic acid); and flow rate of 1 mL/min. The 
products were purified in a 2545 binary gradient module, a 2767 manager collector, and a 2998 photodiode array 
(PDA) detector (Waters), with Masslynx version 4.1 (Waters), and a SunFire C18 column (150 × 10 mm × 5 µm, 
100 Å, Waters); solvents: H2O (0.1% TFA) and CH3CN (0.1% TFA); and flow rate of 3 mL/min. Graphics were 
performed using GraphPad Prism version 6.01 for Windows (GraphPad Software, La Jolla, CA, USA).
General Protocol for SPPS. All peptides were synthesized by standard 9-fluorenylmethoxycarbonyl/
tert-butyl (Fmoc/tBu) solid-phase peptide synthesis (SPPS). Syntheses were performed on a 200-µmol scale 
using a Fmoc-Rink-Amide p-MBHA resin2,48. Standard solid-phase peptide elongation and other solid-phase 
manipulations were done manually in polypropylene syringes, each fitted with a polyethylene porous disk at 
the bottom. Solvents and soluble reagents were removed by suction. Between couplings and deprotections, the 
resin was washed with DMF (5 × 1 min), DCM (5 × 1 min), and DMF (5 × 1 min), using 5 mL of solvent/g of 
resin each time. During couplings, the syringe was left under automatic stirring. Intermittent manual stirring 
was applied during deprotections. After each reaction, the Kaiser test49 was used to identify primary amines on 
the N-terminus of the elongating peptide on the solid support. The chloranil test50 was used to identify second-
ary amines. Resin was conditioned by washing with DCM (5 × 1 min) and DMF (5 × 1 min), followed by 20% 
piperidine in DMF (1 × 1 min, 2 × 10 min) to remove the Fmoc group. Finally, the resin was washed with DMF 
(5 × 1 min). Fmoc group was removed by treating the resin with 20% piperidine in DMF (3–4 mL/g of resin; 
1 × 1 min, 2 × 10 min). For secondary amine Fmoc deprotection, resin was additionally treated with DBU, tolu-
ene, and piperidine in DMF (5:5:20:70, v/v) (1 × 10 min). Nα-Fmoc-protected amino acids (4 eq.), TBTU (4 eq.) 
and DIEA (8 eq.) were used for the coupling onto primary amines. For the coupling onto proline, TBTU was 
replaced by PyBOP (4 eq.) and HOBt (12 eq.). Carboxyfluorescein (Cf) was coupled at the N-terminal part of the 
peptides when required using the same coupling steps.
N-Methylation. Amino acid derivatives were N-methylated using the method described by Miller et al.47. 
This process can be divided into three steps: protection and activation with o-nitrobenzensulfonyl chloride 
Figure 5. Peptide internalization by cells. Confocal laser scanning microscopy (CLSM) images of (a,d) 
BBECs and (b,e) rat astrocytes incubated with the candidates at a concentration of 50 μM at 37 °C for 3 h. 
Flow cytometry results (mean ± SD) after incubating (c) BBECs and (f) rat astrocytes with the candidates at a 
concentration of 50 μM (peptide 3 was incubated at 15 μM) for 3 h at 37 °C.
Peptide
Caco-2 BBB
Papp (×10−10 cm/s) Peptide Papp (×10−6 cm/s) T (%)
HAI 2.0 ± 0.8 0.7 ± 0.3 9 ± 5 10 ± 3
rD-HAI 1.2 ± 1.0 0.4 ± 0.3 14 ± 2 17 ± 3
(NMe)HAI 0.60 ± 0.01 0.200 ± 0.003 11.7 ± 1.3 13.9 ± 1.6
Table 2. Caco-2 and in vitro bovine BBB model permeability results (mean ± SD). Candidates were incubated 
for 2 h at 37 °C using HBSS as buffer, and then analyzed by RP-HPLC to determine transport and Papp.
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(o-NBS), deprotonation and methylation, and o-NBS removal. This method is not suitable for the N-alkylation of 
the first amino acid anchored onto the resin. Hence, the commercially available Fmoc-(Nα-Me)-L-His(Trt)-OH 
was employed as first coupled amino acid for the synthesis of H-HA(NMe)I(NMe)YPR(NMe)H-NH2 and 
Cf-HA(NMe)I(NMe)YPR(NMe)H-NH2. To perform the protection, o-NBS (3 eq.) and collidine (5 eq.) in DCM 
were added to the resin and left for 60 min. This step was repeated once and the completion of the reaction was 
monitored by the ninhydrin test. Methyl p-nitrobenzensulfonate (4 eq.) and 7-methyl-1,5,7-triazabicyclo[4.4.0]
dec-5-ene (3 eq.) in DMF were added to the resin and left for 30 min. This step was repeated once. To remove 
o-NBS, β-mercaptoethanol (10 eq.) and DBU (5 eq.) in DMF were added to the resin and left to react for 10 min 
under N2 atmosphere. This operation was repeated once for 40 min.
Peptide Cleavage. Final amide peptides were cleaved from the resin by treatment with a mixture of TFA/
H2O/EDT/TIS, 94:2.5:2.5:1 (v/v) for 1 h.
Work-Up. After evaporation of the cleavage cocktail, 20 mL of methyl tert-butyl ether (MTBE) was added to 
the plastic tube containing the dry residue. This tube was centrifuged at 2,000 × g for 10 min. The solvent was then 
discarded by decantation. This process was repeated two more times. After the last washing with MTBE, the final 
residue was dissolved in H2O/CH3CN (1:1) and then lyophilized.
Peptide Purification and Characterization. Peptides were purified by RP-HPLC using a SunFire C18 
column. Compound identity was confirmed using MALDI-TOF MS. Peptide purity was checked by RP-HPLC 
using a SunFire C18 column. Circular dichroism spectra were recorded with a Jasco 810 UV-Vis spectropolarime-
ter, with a Peltier CDF 426 S/426 L. The spectra were obtained in a wavelength range of 190 to 250 nm, with a time 
response of 4 s, a scan speed of 10 nm/min, a step resolution of 0.1 nm, and three accumulations.
Internalization of Peptides and Confocal Laser Scanning Microscopy Analysis. Primary cultures 
(rat astrocytes) were seeded onto Petri dishes or glass-bottom Petri dishes at a concentration of 40·103 cells/cm2; 
experiments were carried out 48 h later. On the other hand, immortalized cell lines (BBECs) were seeded onto 
Petri dishes or glass-bottom Petri dishes at a concentration of 21.4·103 cells/cm2; experiments were carried out 
24 h later. Then, cells were incubated with peptides at a concentration of 50 μM (except R8 –incubated at a con-
centration of 15 μM) for 3 h at 37 °C under 5% CO2 in DMEM. They were then washed five times with DMEM 
without phenol red and confocal laser scanning microscopy analysis was performed. For co-localization experi-
ments with transferrin protein, peptides were co-incubated with AlexaFluor555-transferrin at a concentration of 
50 mg/mL. To prevent crosstalk, emission signals were recorded sequentially. Confocal microscopy images were 
recorded using an Olympus Fluoview 500 inverted confocal microscope with a 60×/1.4 NA objective, equipped 
with a 488 nm line of an argon laser, and a 543 nm HeNe laser; or a Leica TCS SPE system (DM 2500) spectral 
confocal microscope with a 63×/1.3 and a 40×/1.15 oil CS objective, equipped with the following diode lasers: 
405, 488, 532 and 635 nm.
MTT Toxicity Assay. The assay was performed in 96-well plates, adding 3,150 cells to each well in 100 μL 
(immortalized cell line –i.e. BBECs) or 7,000 cells in 100 μL (primary cultures –i.e. rat astrocytes), seeded 24 h 
before performing the experiment. Cells were incubated with each peptide at a range of concentrations (20, 50 
and 500 μM) in cellular medium for 24 h at 37 °C and 5% CO2. After 22 h, MTT (3-(4,5-dimethylthiazol-2-yl)−2
,5-diphenyltetrazolium bromide) was added to a final concentration of 0.5 mg/mL. The cells with peptides and 
MTT were incubated for further 2 h. The medium was then discarded and 200 μL of 2-propanol was added to each 
well to dissolve the purple formazan, product of the conversion of MTT by the mitochondrial enzyme NADH 
dehydrogenase. The plate was kept in an orbital shaker for 30 min (15 rpm) to ensure the complete dissolution 
of formazan. Finally, absorbance was measured at 570 nm and cell viability percentages were calculated dividing 
the absorbance value of cells treated with a given peptide by the absorbance value of untreated cells. Experiments 
for each peptide were carried out by triplicate. Cells incubated with 1% SDS were used as control of 0% viability 
(value subtracted to all samples before viability calculus per each peptide).
Synthesis and Characterization of the AuNP-Peptide. AuNPs synthesis, conjugation and character-
ization were performed as previously reported by Prades et al.11. Briefly, a Cys residue was introduced in the 
C-terminal end of the peptides to enable the conjugation to AuNPs. AuNPs were conjugated to the peptides by 
mixing a solution of AuNPs (5 nM, 10 mL) and the corresponding peptide (0,1 mg/mL, 1 mL). The free peptide 
was eliminated by dialysis using a MWCO 6–8000 (Spectra/Por) membrane. The peptide load of AuNPs was 
calculated by dividing peptide grafted to NPs and number of NPs, which was estimated according to Liu et al.51. 
The concentration of AuNPs in the solution was obtained from the gold-content determined by ICP-MS and 
the average size obtained by TEM. The peptide concentration was determined by amino acid analysis (AAA). 
Zeta-potential and DLS measurements were obtained in a Malvern Zetasizer Nano ZS (Malvern Instruments), at 
25 °C using a 3-mm light path cuvette. The refractive index was considered 1.4. Cell viability was assessed using a 
tetrazolium salt reduction assay (CellTiter 96) using SH-SY5Y.
In vivo Experiments with the AuNP-Peptide. All animal experimental protocols were approved 
by the Local Bioethics Committee of the School of Pharmacy of the University of Chile (CBE-2012-21). All 
methods were carried out in accordance with guidelines and regulations animal procedures of Springer Nature. 
Experiments were performed as previously reported by Prades et al.11. Briefly, male Sprague Dawley rats (180–
200 g body weight) were randomly divided into groups of 4 animals each and one control group (treated with 
sodium citrate 2.2 mM). AuNPs, AuNP-HAI and AuNP-THR were injected intraperitoneally (1.86 mg gold/kg 
www.nature.com/scientificreports/
9ScIenTIfIc REPORTS |         (2018) 8:17932  | DOI:10.1038/s41598-018-35938-8
of body weight) and gold content was analyzed at three time points (0.5, 1 and 2 h). AuNP-THR conjugates 
data were extracted from Prades et al.11. Instrumental neutron activation analysis (INAA) was used to measure 
the amount of gold in brains.
In vitro Bovine BBB Cell-Based Model Assay. This assay was an adapted model10 of the method pre-
viously published by Gaillard and de Boer52. Briefly, TEER was measured in all transwells (TEER > 100 Ω·cm2), 
before performing the assay. Peptides were prepared at a concentration of 200 μM in Ringer-HEPES buffer con-
taining 20 μM Lucifer yellow (LY) lithium salt (Sigma-Aldrich) as control (Papp < 17·10−6 cm/s). The apical com-
partment was filled with 200 μL of the solution containing the peptide, and 800 µL of Ringer-HEPES was poured 
into the basal well. Three replicates of each peptide were assayed. The plate was left for 2 h in the incubator at 
37 °C. Finally, the samples were collected and analyzed or frozen until analysis. LY fluorescence was measured 
in a 96-well plate with a Fluoroskan Ascent Microplate Fluorometer (Thermo Fisher Scientific). TfR expression 
was confirmed by immunohistochemistry, as subsequently described. Usually on day 8 of co-culture (maximum 
TEER data obtained), the cells attached to the transwell filter were rinsed with PBS and fixed in a 4% paraformal-
dehyde solution in PBS for 10 min at room temperature. Cells were rinsed three times with PBS, and the reactivity 
of aldehyde groups was blocked by addition of 50 mM NH4Cl in PBS for 20 min at room temperature, after which 
cells were washed with PBS. The next step involved the blocking of further unspecific binding and cell membrane 
permeabilization, which was achieved by adding a solution of 0.1% saponin and 1% BSA in PBS for 10 min at 
room temperature. Insert filters were then washed by immersion in PBS at room temperature. Filters were then 
cut using a scalpel and the filter face where cells were attached was incubated with 12 µL of the corresponding 
primary anti-TfR antibody in a solution of PBS and 1% BSA for 1 h. Filters were washed by immersion in PBS 
(2 × 5 min) at room temperature and incubated with 12 µL of the secondary antibody in a solution of PBS, 1% 
BSA and DAPI for 1 h. Filters were washed 4 times with PBS at room temperature and placed on a glass slide. 
15 µL of Mowiol was added to each filter, and a cover slide was placed over each one. Glass slides with filters were 
stored at 4 °C protected from light until confocal microscopy analysis.
Caco-2 Intestinal Barrier Model Assay. The ability of peptides to overcome the intestinal barrier was 
tested using Caco-2 cells. Transport studies were conducted by the BioFarma Research group at University 
of Santiago de Compostela. Briefly, experiments were done with cells (passage between 60 and 80) seeded on 
4.67 cm2 filters at a density of 5.25·104 cell/cm2. Peptides dissolved in HBSS were incubated for 2 h at a 50 μM 
concentration with cell layers at 37 °C and 5% CO2. After the experiment, the content of each compartment was 
directly analyzed by HPLC and then transport (in %) and Papp were determined.
In vitro Human BBB Cell-Based Model Assay. This assay was performed using the model published 
by Cecchelli and co-workers53. Endothelial cells and pericytes were defrosted in gelatin-coated Petri dishes 
(Corning). Pericytes and endothelial cells were cultured in DMEM pH 6.8 or in supplemented endothelial cell 
growth medium (Sciencells), respectively. After 48 h, pericytes (50,000 cells/well) and endothelial cells (80,000 
cells/well) were seeded in gelatin-coated 12-well plates or in Matrigel-coated 12-well Transwell inserts (Corning), 
respectively. Medium was changed every 2–3 days and assays were performed 7–8 days after seeding. Lucifer 
Yellow (50 µM) was used as internal control (Papp < 15·10−6 cm/s). LY fluorescence was measured in a 96-well 
plate with a Fluoroskan Ascent Microplate Fluorometer (Thermo Fisher Scientific). Compounds were dissolved 
in Ringer-HEPES at a concentration of 200 µM. Then, 500 µL of the compound and 1,500 µL of Ringer-HEPES 
alone were introduced in the apical or in the basolateral compartments, respectively. The plates were set on at 
37 °C for 2 h. The solutions from both compartments were then recovered and quantified by HPLC and identified 
by MALDI-TOF.
Peptide Stability in Human Serum. Peptides were dissolved in 1 mL of HBSS buffer/human serum (from 
human male AB plasma; Sigma-Aldrich) 10:90 (v/v) at a final concentration of 200 µM and incubated at 37 °C 
for 24 h. Aliquots of 50 µL were extracted at a range of incubation times and treated with 200 µL of cold CH3OH 
(4 °C) to precipitate serum proteins. After 30 min, samples were centrifuged at 13,000 g and 4 °C for 30 min. 
Supernatants were analyzed by RP-HPLC-PDA and MALDI-TOF MS, using similar procedures as for the quan-
tification of the in vitro cell-based BBB model.
Statistical Analysis. The t-test was for the comparison of two groups. A one-way ANOVA test was selected 
for multiple comparison analyses. A 5% level was chosen for significance of group. Prior to the statistical data 
analyses, raw data was sublimated to the Grubb’s test for the detection of outliers.
Data Availability Statement
All the relevant data supporting the findings are available from the corresponding author on reasonable request.
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